PL411635A1 - Kompozycja farmaceutyczna zawierająca kwas foliowy oraz sól glukozaminową kwasu (6S)-5-metylotetrahydrofoliowego oraz jej zastosowanie - Google Patents

Kompozycja farmaceutyczna zawierająca kwas foliowy oraz sól glukozaminową kwasu (6S)-5-metylotetrahydrofoliowego oraz jej zastosowanie

Info

Publication number
PL411635A1
PL411635A1 PL411635A PL41163515A PL411635A1 PL 411635 A1 PL411635 A1 PL 411635A1 PL 411635 A PL411635 A PL 411635A PL 41163515 A PL41163515 A PL 41163515A PL 411635 A1 PL411635 A1 PL 411635A1
Authority
PL
Poland
Prior art keywords
pharmaceutical composition
acid
application
composition containing
glucosamine salt
Prior art date
Application number
PL411635A
Other languages
English (en)
Inventor
Jarosław Wypych
Aneta Pakieła-Rajtkowska
Original Assignee
Sequoia Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sequoia Spółka Z Ograniczoną Odpowiedzialnością filed Critical Sequoia Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL411635A priority Critical patent/PL411635A1/pl
Priority to PCT/IB2015/060027 priority patent/WO2016147040A1/en
Priority to EP15828535.3A priority patent/EP3270927A1/en
Publication of PL411635A1 publication Critical patent/PL411635A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Abstract

Przedmiotem wynalazku jest kompozycja farmaceutyczna zawierająca terapeutycznie skuteczną ilość kwasu foliowego oraz sól glukozaminową kwasu metylotetrahydrofoliowego do stosowania w profilaktyce wad cewy nerwowej u płodu oraz w niedoborach folianów i kwasu foliowego w anemii i niedoborach żelaza.
PL411635A 2015-03-18 2015-03-18 Kompozycja farmaceutyczna zawierająca kwas foliowy oraz sól glukozaminową kwasu (6S)-5-metylotetrahydrofoliowego oraz jej zastosowanie PL411635A1 (pl)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL411635A PL411635A1 (pl) 2015-03-18 2015-03-18 Kompozycja farmaceutyczna zawierająca kwas foliowy oraz sól glukozaminową kwasu (6S)-5-metylotetrahydrofoliowego oraz jej zastosowanie
PCT/IB2015/060027 WO2016147040A1 (en) 2015-03-18 2015-12-29 Pharmaceutical composition comprising folic acid and (6s)-5-methyltetrahydrofolic acid glucosamine salt and the use thereof
EP15828535.3A EP3270927A1 (en) 2015-03-18 2015-12-29 Pharmaceutical composition comprising folic acid and (6s)-5-methyltetrahydrofolic acid glucosamine salt and the use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL411635A PL411635A1 (pl) 2015-03-18 2015-03-18 Kompozycja farmaceutyczna zawierająca kwas foliowy oraz sól glukozaminową kwasu (6S)-5-metylotetrahydrofoliowego oraz jej zastosowanie

Publications (1)

Publication Number Publication Date
PL411635A1 true PL411635A1 (pl) 2016-09-26

Family

ID=56918505

Family Applications (1)

Application Number Title Priority Date Filing Date
PL411635A PL411635A1 (pl) 2015-03-18 2015-03-18 Kompozycja farmaceutyczna zawierająca kwas foliowy oraz sól glukozaminową kwasu (6S)-5-metylotetrahydrofoliowego oraz jej zastosowanie

Country Status (3)

Country Link
EP (1) EP3270927A1 (pl)
PL (1) PL411635A1 (pl)
WO (1) WO2016147040A1 (pl)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10022510A1 (de) * 2000-05-10 2001-11-15 Basf Ag Zusammensetzungen enthaltend Folsäure und reduziertes Folat
RU2007137460A (ru) * 2005-03-10 2009-04-20 Сайэл Фарма, Инк. (Us) Пищевые препараты
US7947662B2 (en) * 2008-02-20 2011-05-24 Gnosis S.P.A. Folates, compositions and uses thereof
US20140073598A1 (en) * 2012-09-11 2014-03-13 Jaymac Pharmaceuticals Llc Multiple folate formulation and use thereof

Also Published As

Publication number Publication date
EP3270927A1 (en) 2018-01-24
WO2016147040A1 (en) 2016-09-22

Similar Documents

Publication Publication Date Title
CY1120529T1 (el) Προφαρμακα φουμαρικων αλατων και η χρηση τους στην αγωγη ποικιλων νοσων
PH12015500780A1 (en) Rsv antiviral compounds
NZ743964A (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MY179756A (en) Stabilized efinaconazole formulations
MD20170070A2 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
PH12015501648B1 (en) 2-aminopyrimidine derivatives for the treatment of viral infections
MX2015017964A (es) Inhibidores de bromodominio.
CY1119694T1 (el) Ημιθειικο αλας του 5,10-μεθυλενο-(6r)-τετραϋδροφυλλικου οξεος
PH12018500446A1 (en) Pyridinone dicarboxamide for use as bromodomain inhibitors
TN2017000554A1 (en) Novel combination for use in the treatment of cancer
TR201909447T4 (tr) Aramkol tuzları.
MA39710A (fr) Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
MA40583A (fr) Nouveaux activateurs de la guanylate cyclase soluble et leur utilisation
IN2012DE00912A (pl)
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
PH12017500348A1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
MX2015000179A (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
EA201792121A1 (ru) Фармацевтические солевые формы ингибитора семикарбазидчувствительной аминоксидазы (ssao)
EP2983684B8 (en) Essential oil and aloe for treatment and prophylaxis of inflammations caused by demodex, especially marginal blepharitis, a pharmaceutical composition containing essential oil and/or aloe and the use of essential oil and aloe and their compositions for the production of a preparation used in treatment and prophylaxis of the mentioned inflammations
PL3236938T3 (pl) Doustne miejscowe wodne kompozycje farmaceutyczne flurbiprofenu i dekspantenolu
PL411635A1 (pl) Kompozycja farmaceutyczna zawierająca kwas foliowy oraz sól glukozaminową kwasu (6S)-5-metylotetrahydrofoliowego oraz jej zastosowanie
TR201908937T4 (tr) P38 MAP kinazı inhibe eden indanil üre bileşikleri.
MX2016006742A (es) Composicion farmaceutica.